Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Medexus is betting big on GRAFAPEX, but current results show declining performance and high risk.

What the company is saying

Medexus Pharmaceuticals is positioning itself as a growth story centered on the commercial rollout of GRAFAPEX, a new product they claim will transform their revenue base. The company wants investors to believe that, despite recent declines in overall financial performance, GRAFAPEX is gaining traction and will drive substantial future growth. They frame their narrative around the expectation that annual product-level net revenue from GRAFAPEX will exceed $100 million within five years after commercial launch, and that near-term revenue from GRAFAPEX will reach $30–32 million in fiscal year 2027. The announcement emphasizes the number of transplant centers in the United States that have ordered and reordered GRAFAPEX (74 out of 180, with 54 reorders), as well as a claimed 50% sequential quarter-over-quarter growth in patient demand—though the latter is not numerically substantiated. Management’s tone is measured but leans optimistic, highlighting investments in GRAFAPEX infrastructure ($11.2 million in fiscal 2026) and suggesting these investments are already yielding positive results. The communication style is factual but selectively detailed: while headline financials and GRAFAPEX-specific data are disclosed, there is little discussion of the broader portfolio’s performance or the drivers behind the overall revenue and profit declines. Notable individuals named are Ken d'Entremont (CEO) and Brendon Buschman (CFO), both of whom are company insiders; there is no mention of external institutional investors or strategic partners, which limits the perceived external validation of the company’s strategy. This narrative fits a classic pivot-to-growth investor relations strategy, where management seeks to shift focus from deteriorating legacy performance to the promise of a new product. Compared to prior communications (where history is unavailable), the messaging here is heavily weighted toward forward-looking statements and the potential of GRAFAPEX, with less emphasis on realized financial health.

What the data suggests

The disclosed numbers paint a picture of a company under financial pressure, with deteriorating year-over-year performance. Net revenue for fiscal year 2026 was $99.3 million, down $9.0 million (8.3%) from $108.3 million in the prior year. Adjusted EBITDA fell to $16.5 million, an 18.3% decrease from $20.2 million, and operating income dropped sharply by 37.8% to $5.1 million from $8.2 million. Most notably, the company swung from a net income of $2.2 million to a net loss of $2.4 million, indicating that profitability has not only declined but reversed. GRAFAPEX contributed $11.6 million in product-level net revenue for the year, with $3.4 million in the most recent quarter, but this is still a small fraction of the $100 million annual target projected for five years out. The company claims $87.7 million in net revenue from its established portfolio (excluding GRAFAPEX), but this figure is not directly disclosed or broken down, making it impossible to verify. Similarly, the touted 50% quarter-over-quarter growth in GRAFAPEX patient demand is not supported by any underlying data. The financial disclosures are adequate for headline analysis but lack granularity: there is no full product-by-product breakdown, no cash flow statement, and no detailed expense reporting. An independent analyst would conclude that, while GRAFAPEX is showing some early adoption, the company’s overall financial trajectory is negative, and the gap between management’s growth claims and current performance is wide.

Analysis

The announcement presents a largely factual summary of realised financial results, including declines in net revenue, EBITDA, and operating income, as well as a swing to net loss. The only major forward-looking claim is the projection that GRAFAPEX annual product-level net revenue will exceed $100 million within five years after commercial launch, which is long-dated and not yet substantiated by current run-rate ($11.6 million in the most recent year). The company has invested $11.2 million in GRAFAPEX launch infrastructure, but the immediate revenue impact is modest, and the path to the projected $100 million is not clearly evidenced. The tone is measured, but the narrative leans on future potential rather than current performance, especially given the deteriorating financials. The gap between narrative and evidence is moderate: realised GRAFAPEX sales are disclosed, but the long-term revenue target is aspirational and not yet de-risked by binding agreements or demonstrated growth trajectory.

Risk flags

• ●The majority of the company’s positive claims are forward-looking, particularly the projection that GRAFAPEX will generate over $100 million in annual revenue within five years. This matters because such long-term targets are inherently speculative and subject to numerous market, regulatory, and operational risks. The current run-rate ($11.6 million) is far below the target, and there is no evidence of a binding order book to support the forecast.
• ●Financial performance is deteriorating across all key metrics: net revenue, EBITDA, operating income, and net income have all declined year-over-year, with the company moving from profit to loss. This trend raises concerns about the sustainability of the business if GRAFAPEX does not scale rapidly.
• ●Capital intensity is high, with $11.2 million invested in GRAFAPEX launch infrastructure in fiscal 2026 alone. High upfront investment increases risk if revenue growth does not materialize as projected, potentially straining liquidity and requiring further capital raises.
• ●Disclosure quality is mixed: while headline numbers are provided, there is no full breakdown of revenue by product, no cash flow statement, and no detailed expense reporting. This lack of transparency makes it difficult for investors to fully assess the health of the business or verify management’s claims.
• ●Operational risk is significant, as the company must convert initial orders from 74 transplant centers into sustained, repeat business across the full addressable market of 180 centers in the United States. The fact that only 54 of the 74 have reordered suggests that broad, sticky adoption is not yet proven.
• ●Execution risk is high for the GRAFAPEX ramp: the company must achieve nearly a threefold increase in product-level revenue in a single year (from $11.6 million to $30–32 million) to meet its fiscal 2027 guidance, with no disclosed evidence of a secured pipeline or binding contracts.
• ●There is no mention of external institutional investors, strategic partners, or third-party validation in the announcement. The absence of such support means the company’s growth narrative relies solely on internal projections, which are less credible than those backed by external commitments.
• ●Geographic concentration risk exists, as the GRAFAPEX launch and adoption data are focused on the United States, but the company’s broader operations and liquidity are tied to Canada and Ontario. Any regulatory, reimbursement, or competitive setbacks in the U.S. market could have outsized impact.

Bottom line

For investors, this announcement signals a company in transition, betting heavily on the future success of GRAFAPEX to offset declining performance in its legacy portfolio. The narrative is credible only to the extent that early GRAFAPEX adoption is real, but the numbers show that current sales are modest and nowhere near the scale required to meet management’s ambitious targets. There is no evidence of external institutional validation or binding commercial agreements, so the growth story is entirely management-driven and speculative. To change this assessment, the company would need to disclose signed long-term contracts, a rapidly growing and recurring order book, or clear evidence of accelerating adoption beyond the initial 74 centers. Key metrics to watch in the next reporting period include realized GRAFAPEX revenue, reorder rates, cash burn, and any updates on liquidity or capital needs. Investors should treat this announcement as a weak positive signal—worth monitoring, but not actionable as a standalone investment thesis given the high execution risk and deteriorating financials. The most important takeaway is that Medexus’s future now hinges almost entirely on GRAFAPEX, and unless the company can rapidly scale sales and demonstrate sustainable profitability, the downside risks remain substantial.

Announcement summary

(TSX: MDP) (OTCQX: MEDXF) Medexus Pharmaceuticals announced its operating and financial results for the fourth fiscal quarter and fiscal year ended March 31, 2026. Net revenue for fiscal year 2026 was $99.3 million, a decrease of $9.0 million, or 8.3%, compared to $108.3 million for the prior year, with $11.6 million of product-level net revenue from GRAFAPEX. Adjusted EBITDA* for fiscal year 2026 was $16.5 million, down $3.7 million, or 18.3%, from $20.2 million in the prior year, while operating income was $5.1 million for fiscal year 2026, a decrease of $3.1 million, or 37.8%. Net loss for fiscal year 2026 was $2.4 million, compared to net income of $2.2 million in the prior year. As of March 31, 2026, available liquidity was $9.0 million, consisting of $6.5 million in cash and cash equivalents and $2.5 million in available credit. The company projects that annual product-level net revenue from GRAFAPEX will exceed $100 million within five years after commercial launch and expects product-level net revenue from GRAFAPEX for fiscal year 2027 will be between $30 million and $32 million.

Disagree with this article?